Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.

Artizan Biosciences, a US-based developer of treatments for inflammatory diseases spun out of Yale University, has collected $11m in a series A2 round co-led by biopharmaceutical company Biohaven Therapeutics. Hatteras Venture Partners co-led the round, which also attracted spinout-focused investment firm Osage University Partners (OUP), Connecticut Innovations and Elm Street Ventures. Artizan is working on…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.